Home 
FOR AUTHORS Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.11, p.785–792,2021
FOR AUTHORS Bratislava Medical Journal 2021 Bratislava Medical Journal Vol.122, No.11, p.785–792,2021
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.122, No.11, p.785–792,2021 |
||
| Title: Therapeutic effect of mesenchymal stem cell therapy in the LVEF, LVEDV, and LVESV after myocardial infarction | ||
| Author: M. M. Rabiei, K. S. Khoramgah, I. A. Darazam, S. Vafaei-Nezhad, S. Dargahi, H. A. Abbaszadeh | ||
| Abstract: OBJECTIVES: The present study was aimed to investigate the therapeutic effect of mesenchymal Stem Cell Therapy in the left ventricular ejection fraction (LVEF), left ventricular enddiastolic volume (LVEDV), and left ventricular endsystolic volume (LVESV) after myocardial infarction (MI). BACKGROUND: Previous investigations propose that stem cell therapy may help treat myocardial infarction (MI). However, there are controversial data from different studies. METHODS: We studied the relevant scientific literature available up to 2020. Comprehensive Meta-Analysis Software (CMAS) Version 2.0 were used for statistical analyses. Fixed or random-effect model was used to identify the weighted mean difference (WMD) with 95% confidence intervals (CI). The statistically significant level used for interpreting publication bias was less than 0.05. RESULTS: We identified 30 studies that met the inclusion criteria. In the overall pooled estimate, cell therapy had an effect on the LVEF change from baseline to follow-up (WMD: 2.98 mL, 95% CI: 1.66 to 4.29). The pooled WMD was found to be –4.16 (95% CI: –7.91 to –0.40) and –5.62 (95% CI: –9.20 to –2.00), for LVEDV, and LVESV, respectively. Thus, reduction in LVEDV and LVESV were significant in the treatment group participants. CONCLUSIONS: The present systematic review indicated that cell therapy in patients, who have MI could be effective and applicable clinically (Tab. 3, Fig. 7, Ref. 48). Text in PDF www.elis.sk |
||
| Keywords: myocardial infarction, stem cell, systematic review, randomized clinical trials | ||
| Published online: 21-Oct-2021 | ||
| Year: 2021, Volume: 122, Issue: 11 | Page From: 785, Page To: 792 | |
| doi:10.4149/BLL_2021_125 |
||
|
|
 download file |
|